<i>UMOD</i> Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide.

ABSTRACT:

Background

UMOD (uromodulin) has been linked to hypertension through potential activation of Na⁺-K⁺-2Cl^- cotransporter (NKCC2), a target of loop diuretics. We posited that hypertensive patients carrying the rs13333226-AA UMOD genotype would demonstrate greater blood pressure responses to loop diuretics, potentially mediated by this UMOD/NKCC2 interaction.

Methods

This prospective, multicenter, genotype-blinded trial evaluated torasemide (torsemide) efficacy on systolic blood pressure (SBP) reduction over 16 weeks in nondiabetic, hypertensive participants uncontrolled on ≥1 nondiuretic antihypertensive for >3 months. The primary end point was the change in 24-hour ambulatory SBP (ABPM SBP) and SBP response trajectories between baseline

SUBMITTER: McCallum L 

PROVIDER: S-EPMC11460757 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature